A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia

Trial Profile

A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Lintuzumab Ac-225 (Primary) ; Cytarabine; Furosemide; Spironolactone
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Actinium Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2017 According to an Actinium Pharmaceuticals media release, data from phase II part will be presented at the 59th Annual American Society of Hematology (ASH) Meeting & Exposition.
    • 04 Oct 2017 According to an Actinium Pharmaceuticals media release, trial is now active at 16 clinical trials sites and a planned interim analysis is expected by the end of 2017 and top line data in the first half of 2018.
    • 13 Sep 2017 According to an Actinium Pharmaceuticals media release, updates from the study will be presented at the Society of Hematologic Oncology 2017 Annual Meeting (SOHO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top